Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All three provided claims match the supplied prescribing information excerpts for indications/usage criteria (age/weighing threshold omitted in claims but not contradicted) and the specified post-transplant CMV infection/disease refractory or intolerance to the listed antivirals.
Category Scores
Accurate Statements
Livtencity (maribavir) received FDA approval on June 25, 2021 under NDA 215596.
Not verifiable from the prescribing information excerpts provided in the prompt (sections 1/2/5/7/12 only).
Livtencity (maribavir) is approved for the treatment of adult and pediatric patients aged 12 years and older who are post-transplant and have refractory cytomegalovirus (CMV) infection.
Supported by Label section 1: indicated for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.
Livtencity (maribavir) is approved for the treatment of adult and pediatric patients aged 12 years and older who are post-transplant and have intolerance to ganciclovir, valganciclovir, cidofovir, or foscarnet.
Supported by Label section 1: indicated for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir/valganciclovir/cidofovir/foscarnet.
Unsupported Statements
Livtencity (maribavir) received FDA approval on June 25, 2021 under NDA 215596.
No approval date/NDA number information is present in the provided prescribing information excerpts.
Contradictions
Important Omissions
The prescribing information in section 1 specifies pediatric patients must be 12 years of age and older AND weighing at least 35 kg; the claims state 'aged 12 years and older' without the weight criterion.
Importance:
Moderate
The section 1 label text characterizes the population as 'refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet'; the first indication claim omits 'with or without genotypic resistance' and omits explicitly that refractoriness is to those specific agents.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No contraindications, warnings, dosing, or interaction safety claims were made. Main gaps are omission of a pediatric weight threshold and some label nuances in the wording of indication criteria.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the 'weighing at least 35 kg' pediatric criterion and some label nuance regarding refractoriness criteria.
Suggested Improvement
Include the full label eligibility wording from section 1 (12 years and older AND weighing at least 35 kg; specify refractory to treatment with ganciclovir/valganciclovir/cidofovir/foscarnet, and include 'with or without genotypic resistance' if referencing refractoriness).